🇺🇸 NBIX — Neurocrine Biosciences, Inc.

Salud Compra fuerte
← Volver

Precio actual

164,63 USD

Máx. histórico

185,50

99 días

Caída desde máximo

-11,25%

Rango 52 semanas

122,14 – 186,12

Variación hoy

+3,05%

Cierre anterior

159,76

Rango de hoy

158,66 – 165,86

Volumen hoy

1.507.456

Peor caída histórica

-97,21%

15/03/2006 → 12/11/2009

Recuperado en 2911 días

Volatilidad anualizada ⓘ

61,30%

Información
Nombre completo
Neurocrine Biosciences, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Drug Manufacturers - Specialty & Generic
Empleados
2.500
PER ⓘ
24,43 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
207,50 USD (puede no estar actualizado)
Primera cotización
23/05/1996
Precio actualizado
hace 21 horas
Sobre la empresa

Neurocrine Biosciences, Inc. discovers, develops, and commercialize pharmaceuticals for neurological, psychiatric, endocrine, and immunological disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; Orilissa tablets for endometriosis; Oriahnn capsules to treat uterine fibroids; and CRENESSITY to treat congenital adrenal hyperplasia, as well as offers products under the name of ALKINDI and Efmody. Its product candidates in clinical development includes NBI-1076986 to treat movement disorders; Osavampator for inadequate response to treatment in major depressive disorder; NBI-1117568 for the treatment of schizophrenia and bipolar mania; NBI-1117567 for the treatment of Alzheimer's disease; NBI 921355 for the treatment of epilepsy; NBIP-01435 for the treatment of congenital adrenal hyperplasia; NBIP-2118 for the treatment of obesity and related metabolic diseases; and NBI-1070770 to treat major depressive disorder; and NBI-1117570, NBI-1117567, NBI-1117569, NBI-1140675, and NBI-1065890 for neuropsychiatric and neurological conditions. The company also has license and collaboration agreements with Nxera Pharma UK Limited; Takeda Pharmaceutical Company Limited; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; Sanofi S.A.; Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
18/11/2002 46,40 46,44 45,10 45,69 -2,06% 2,89% 580.500
15/11/2002 47,25 47,25 46,07 46,65 -2,81% 2,50% 1.058.800
14/11/2002 47,00 48,24 46,49 48,00 +3,69% 3,72% 1.333.000
13/11/2002 46,39 46,98 45,30 46,29 -0,24% 3,62% 733.000
12/11/2002 46,00 46,55 45,20 46,40 +0,96% 2,93% 578.300
11/11/2002 46,20 46,85 45,60 45,96 -0,41% 2,71% 610.000
08/11/2002 47,70 47,70 45,38 46,15 -2,94% 4,86% 841.900
07/11/2002 48,44 48,55 47,09 47,55 -2,38% 3,01% 482.700
06/11/2002 47,20 48,74 46,80 48,71 +2,87% 4,11% 743.400
05/11/2002 46,51 47,35 45,56 47,35 +1,83% 3,85% 398.500
04/11/2002 46,25 46,95 45,63 46,50 +0,63% 2,85% 473.400
01/11/2002 44,98 46,48 43,45 46,21 +2,92% 6,74% 697.600
31/10/2002 44,01 46,20 43,50 44,90 +1,40% 6,13% 1.056.400
30/10/2002 43,08 45,60 43,08 44,28 +3,07% 5,85% 725.000
29/10/2002 42,20 43,10 41,79 42,96 +0,94% 3,10% 518.600
28/10/2002 42,10 42,82 41,85 42,56 +2,01% 2,30% 580.200
25/10/2002 40,32 42,36 39,65 41,72 +3,22% 6,72% 624.100
24/10/2002 41,30 41,75 40,05 40,42 -1,80% 4,12% 398.300
23/10/2002 41,74 41,97 40,94 41,16 -1,65% 2,47% 583.300
22/10/2002 41,98 42,40 41,50 41,85 -1,27% 2,14% 426.100
21/10/2002 42,09 42,69 41,75 42,39 +0,09% 2,23% 613.000
18/10/2002 40,85 42,90 40,84 42,35 +1,80% 5,04% 616.400
17/10/2002 41,25 41,90 40,60 41,60 +1,71% 3,15% 685.700
16/10/2002 40,50 42,20 40,30 40,90 +0,79% 4,69% 539.000
15/10/2002 41,59 42,70 40,51 40,58 -1,29% 5,27% 824.700
14/10/2002 39,75 41,60 39,66 41,11 +2,80% 4,88% 686.500
11/10/2002 40,15 41,23 39,41 39,99 -0,07% 4,53% 503.700
10/10/2002 39,44 40,10 37,92 40,02 +1,01% 5,53% 1.004.800
09/10/2002 40,12 41,20 39,59 39,62 -2,10% 4,01% 497.900
08/10/2002 40,71 41,34 39,96 40,47 -0,93% 3,39% 542.900